BAILLIE GIFFORD & CO 13D and 13G filings for Adaptimmune Therapeutics plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-12 10:25 am Sale | 2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 70,914,570 4.600% | -24,558,270 (-25.72%) | Filing |
| 2024-01-29 11:52 am Sale | 2023-12-29 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 95,472,840 7.010% | -7,546,794 (-7.33%) | Filing |
| 2023-01-18 06:41 am Purchase | 2022-12-30 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 103,019,634 10.480% | 401,082 (+0.39%) | Filing |
| 2022-12-02 07:33 am Purchase | 2022-11-30 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 102,618,552 10.440% | 20,080,440 (+24.33%) | Filing |
| 2022-01-18 07:02 am Purchase | 2021-12-31 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 82,538,112 8.810% | 20,391,432 (+32.81%) | Filing |
| 2021-01-28 06:36 am Purchase | 2020-12-31 | 13G | Adaptimmune Therapeutics plc ADAP | BAILLIE GIFFORD & CO | 62,146,680 6.690% | 62,146,680 (New Position) | Filing |